Skip to main content

Advertisement

Table 2 In vitro antimicrobial and anticancer screening of the synthesized derivatives (126)

From: Benzoxazole derivatives: design, synthesis and biological evaluation

Comp. no. Antimicrobial screening (MIC = ×10−3 µM) Anticancer screening (IC50 = µM)
BS PA EC ST KP AN CA HCT-116
1 2.83 2.83 2.83 2.83 2.83 5.66 0.34 192.5
2 2.65 2.65 5.30 5.30 5.30 5.30 0.66 84.8
3 2.65 2.65 2.65 2.65 2.65 2.65 0.66 > 212.1
4 2.49 4.98 2.49 4.98 2.49 2.49 0.62 39.9
5 2.49 4.98 4.98 2.49 2.49 4.98 1.25 > 199.4
6 1.18 4.70 2.35 2.35 4.70 4.70 0.59 24.5
7 2.58 5.17 2.58 5.17 5.17 5.17 0.65 > 206.8
8 2.45 4.91 4.91 4.91 4.91 4.91 0.61 > 196.3
9 2.68 5.36 5.36 5.36 5.36 2.68 0.67 > 214.4
10 1.14 4.57 2.28 4.57 4.57 4.57 0.57 > 182.6
11 1.28 5.14 5.14 5.14 5.14 5.14 0.64 > 205.5
12 2.57 5.14 5.14 5.14 2.57 5.14 1.28 > 205.5
13 2.57 2.57 5.14 5.14 1.28 5.14 0.64 > 205.5
14 2.63 2.63 2.63 5.25 1.31 5.25 0.66 > 210.1
15 2.63 5.25 5.25 2.63 1.31 5.25 1.31 > 210.1
16 1.22 4.90 2.45 4.90 1.22 4.90 1.22 > 195.9
17 2.52 5.05 2.52 2.52 1.26 2.52 0.63 > 201.8
18 2.72 5.44 2.72 2.72 1.36 5.44 5.44 78.3
19 2.40 4.80 4.80 2.40 4.80 2.40 4.80 > 192.2
20 2.40 4.80 4.80 2.40 4.80 4.80 4.80 > 192.2
21 2.60 5.20 2.60 2.60 5.20 2.60 5.20 > 208.1
22 2.67 2.67 5.35 5.35 5.35 5.35 5.35 70.6
23 2.82 5.65 1.41 2.82 5.65 5.65 5.65 > 226
24 2.79 5.59 1.40 2.79 2.79 2.79 2.79 96.1
25 2.71 5.42 2.71 2.71 5.42 2.71 2.71 45.5
26 2.73 2.73 2.73 2.73 5.46 5.46 5.46 35.6
Ofloxacin 1.73 3.46 3.46 1.73 3.46
Fluconazole 4.08 2.04
5-FU 29.2